Opendata, web and dolomites

AllergyVAX SIGNED

Next generation allergen immunotherapy based on specifically modified recombinant hypoallergens

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AllergyVAX project word cloud

Explore the words cloud of the AllergyVAX project. It provides you a very rough idea of what is the project "AllergyVAX" about.

histamine    modifications    small    burden    clinically    building    managed    symptom    medication    tolerance    dm    months    global    iia    iib    modified    usually    efficacy    economic    serious    dose    symptomatic    bet    reduce    tests    few    immunological    trial    horse    fold    candidates    shorten    risk    days    pipeline    relief    establishing    human    desired    advancing    peanut    school    allergy    pollen    drugs    basis    allergies    causes    transition    million    shown    grass    modifying    temporarily    tolerate    training    monthly    rbet    hypoallergens    immune    preclinical    relatively    treatment    takes    natural    patients    drops    asthma    missed    maximum    immunogenicity    birch    injectable    alleviates    immunotherapy    injections    daily    compromising    clinical    dog    mice    ait    reactions    tolerated    tablets    proteins    symptoms    dozens    hypoallergen    release    platform    allergen    seamless    rhinitis    date    launch    billion    avoiding    social    people    allergic    created    allergyvax    popularity    allergens    disease    trigger   

Project "AllergyVAX" data sheet

The following table provides information about the project.

Coordinator
DESENTUM OY 

Organization address
address: RUNEBERGINKATU 49 A 22 LEXWELL OY
city: HELSINKI
postcode: 260
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Total cost 3˙684˙750 €
 EC max contribution 1˙885˙000 € (51%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DESENTUM OY FI (HELSINKI) coordinator 1˙885˙000.00

Map

 Project objective

Allergy is a rapidly increasing, global problem that already affects 1 billion people and causes significant social and economic burden. In Europe, allergic rhinitis and asthma cause more than 100 million missed work and school days per year. Allergy is usually managed by avoiding the allergen or by medication that temporarily alleviates the symptoms. The only disease-modifying treatment available to date is allergen immunotherapy (AIT) where long-term symptom relief is achieved by training the immune system to tolerate allergens. However, typical AIT takes 3-5 years, involves monthly injections or daily drops/tablets and has the risk of serious allergic reactions during treatment. Thus, the popularity of AIT is still relatively low compared to symptomatic drugs. We have developed a platform technology for creating modified hypoallergens to be used in AIT. It is based on making small, highly targeted modifications to allergen proteins that reduce their ability to trigger allergic reactions during treatment without compromising their efficacy in building tolerance to natural allergens. With these modified hypoallergens, we expect to shorten the injectable AIT treatment from dozens of injections over 3 years to just 3-6 injections over a few months. From the clinically important major birch pollen allergen Bet v 1 we have created rBet v 1 dm hypoallergen. In preclinical tests it has shown 100-fold reduction in histamine release compared to natural allergens and induced similar immunological responses in mice that are desired in human AIT. In the AllergyVAX project we will test rBet v 1 dm for maximum tolerated dose and immunogenicity in allergic patients in a phase I/IIa clinical trial. The project will facilitate seamless transition to phase IIb-III clinical development, establishing a basis for product launch with selected partners and advancing other hypoallergens in the pipeline, including product candidates for grass pollen, dog, horse and peanut allergies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ALLERGYVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ALLERGYVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More